EUVIMEDEUVIMED entdecken
Crossref

Impact of Adjuvant Immune Checkpoint Inhibitors and Chemotherapy on Survival Outcomes in High‐Risk Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study

Satoshi Washino, Go Kaneko, Tomokazu Sazuka, Shoichi Nagamoto, Yuki Nakamura, Akinori Nakayama, Kohei Mito, Kosuke Kazashi, Kimitoshi Saito, Sumire Takeuchi, Akihiro Yano, Tomoaki Miyagawa

International Journal of Urology · 2026-11 · 33 (11)

DOI: 10.1111/iju.70721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 16.11.2026. Verfasst von Satoshi Washino und 11 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The efficacy of adjuvant immune checkpoint inhibitor (ICI) after radical nephroureterectomy compared with observation or adjuvant chemotherapy in patients with upper tract urothelial carcinoma (UTUC) at high risk of recurrence remains uncertain. This multicenter retrospective study evaluated the impact of adjuvant ICI and chemotherapy on survival outcomes in high‐risk UTUC.

Methods

A total of 243 patients with high‐risk UTUC were categorized into three groups: no adjuvant therapy ( n = 151), adjuvant chemotherapy ( n = 59), and adjuvant ICI ( n = 33). Disease‐free survival (DFS) was the primary endpoint, and non‐urothelial tract and urothelial tract recurrence‐free survival were also assessed. Univariable and multivariable Cox proportional hazards analyses were performed to evaluate factors associated with DFS.

Results

Baseline clinicopathological characteristics were largely comparable among the groups. In multivariable Cox proportional hazards analyses of the 2‐month landmark cohort, adjuvant chemotherapy (HR, 0.540; 95% CI, 0.338–0.846; p = 0.007) and adjuvant ICI (HR, 0.374; 95% CI, 0.175–0.721; p = 0.003) were each associated with a lower hazard of DFS events than no adjuvant therapy. Adjuvant ICI was associated with longer non‐urothelial tract recurrence‐free survival compared with no adjuvant therapy, whereas urothelial tract recurrence‐free survival did not differ significantly among the groups.

Conclusion

Both adjuvant ICI and adjuvant chemotherapy were associated with longer DFS after radical nephroureterectomy in patients with high‐risk UTUC. Longer follow‐up and prospective studies are needed to assess the durability of this association and the comparative effectiveness between adjuvant ICI and adjuvant chemotherapy.

Zitieren

APA

Washino, S., Kaneko, G., Sazuka, T., Nagamoto, S., Nakamura, Y., Nakayama, A., Mito, K., Kazashi, K., Saito, K., Takeuchi, S., Yano, A., & Miyagawa, T. (2026). Impact of Adjuvant Immune Checkpoint Inhibitors and Chemotherapy on Survival Outcomes in High‐Risk Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study. International Journal of Urology, 33(11). https://doi.org/10.1111/iju.70721

Vancouver

Washino S, Kaneko G, Sazuka T, Nagamoto S, Nakamura Y, Nakayama A, et al. Impact of Adjuvant Immune Checkpoint Inhibitors and Chemotherapy on Survival Outcomes in High‐Risk Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study. International Journal of Urology. 2026;33(11). doi:10.1111/iju.70721

BibTeX
@article{Washino2026,
  author = {Washino, Satoshi and Kaneko, Go and Sazuka, Tomokazu and Nagamoto, Shoichi and Nakamura, Yuki and Nakayama, Akinori and Mito, Kohei and Kazashi, Kosuke and Saito, Kimitoshi and Takeuchi, Sumire and Yano, Akihiro and Miyagawa, Tomoaki},
  title = {Impact of Adjuvant Immune Checkpoint Inhibitors and Chemotherapy on Survival Outcomes in High‐Risk Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study},
  journal = {International Journal of Urology},
  year = {2026},
  volume = {33},
  number = {11},
  doi = {10.1111/iju.70721}
}
Kostenlos starten →